Phase 1 Huntington's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been confirmed through genetic testing to have Huntington's disease (HD), with a specific gene repeat length of 40 or more.
- Your HD has been assessed and falls into a category called "Stage 2" or "Mild Stage 3" based on a standard HD staging system used by the trial team at your screening appointment.
- If you or your partner could become pregnant, you must be willing to use a reliable form of birth control throughout the trial and for at least 90 days after it ends.
Who may not be able to join:
- You have a health condition that would make it unsafe or not possible to have a lumbar puncture (a procedure to collect fluid from your spine) or an MRI scan.
- You have another significant illness affecting your brain, nervous system, or overall health.
- You currently have, or have had, HIV, hepatitis B, or hepatitis C.
- You have recently used an experimental medicine or a treatment specifically designed to lower huntingtin levels in the body (confirm with trial site for exact timeframes).
- You have a psychiatric condition or substance use problem that is not well controlled.
- You are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Please note that additional eligibility criteria not listed here may also apply.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Sarepta Therapeutics, Inc.
Phone: 1-888-SAREPTA (1-888-727-3782)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.